Dr Patricia Zilliox, Chief Executive Officer

Patricia brings over 25 years of expertise in global clinical development in ophthalmology. She was most recently Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia, USA. Prior to that, Patricia was head of clinical development at Alcon Laboratories, managing clinical development programs in areas of eye diseases such as glaucoma, allergy, dry eye, infectious diseases of the eye, and retinal diseases such as dry- and wet-AMD. She also worked for Alcon in Paris, France, where she was responsible for the execution of Alcon’s European ophthalmology clinical trials.

Dr Francine Behar-Cohen, MD, Founder & Chief Innovation Officer

Francine founded Eyevensys in December 2008. From 2013 to 2016, she was the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She is Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of the “Physiopathology of Ocular Diseases” lab at the Cordeliers INSERM Centre. She has authored over 164 publications since 1999. Very entrepreneurially oriented, Francine also founded Eyegate Pharma in 1997.

Dr Ronald Buggage, MD, Chief Medical Officer

Ronald brings more than 14 years experience from both large pharma and biotech companies having worked in senior development positions in the US and Europe.

Ronald was most recently Division Medical Officer at Sanofi’s Ophthalmology Unit, responsible for the leadership and coordination of medical and scientific activities for its ophthalmology portfolio including development programs for ocular gene therapy. He also served as Chief Scientific Officer of Novagali Pharma, where he was responsible for the global clinical and regulatory strategy; Novagali Pharma was successfully acquired by Santen. Prior to moving to France, Dr Buggage held various positions of increasing clinical development responsibility at Novartis and Pfizer. Dr Buggage obtained his MD at UCLA School of Medicine, specializing in ophthalmology at Emory, and completed his training in ocular immunology and uveitis at the National Eye Institute of the National Institutes of Health (NIH).

Dr Thierry Bordet, Chief Scientific Officer

Thierry brings more than 15 years experience in the biotechnology sector having managed drug discovery and drug development programs for small molecules, gene therapies, cell-based therapies and regenerative medicine.

Earlier in his career, as Scientific Project Leader in drug discovery programs for motor neuron disorders and subsequently as Head of CNS Pharmacology at Trophos, Thierry played a key role in the identification and preclinical development of olesoxime, the company’s lead compound which proved to be active in a phase 3 clinical trial for Spinal Muscular Atrophy. After Trophos' acquisition by Roche, he became the Director of Preclinical Development at the Biotherapies Institute for Rare Diseases in Evry (France) where he conducted development strategies for advanced therapy medicinal products for various indications, including Crigler-Najjar syndrome and retinitis pigmentosa.

Thierry is a graduate from Ecole Normale Supérieure de Lyon (ENS Lyon) and holds a Ph.D in Microbiology and Virology from Pierre and Marie Curie University (Paris VI). 

Helene Mortimer

Hélène brings over 15 years of experience in clinical operations and global clinical research development in the US and Europe. Hélène joined Eyevensys after leading complex pivotal trials for Astra Zeneca’s high priority immunotherapy cancer program. Her experience includes all phases and aspects of clinical trials from US academic research centers, CRO, Biotech & large Pharma. This experience, combined with her project management qualifications and skill set, provides the clinical operations management that will drive Eyevensys trials forward.